Oramed Secures Hong Kong Patent For Oral Insulin Administration
The Intellectual Property Department of Hong Kong has granted Jerusalem, Israel-based Oramed Pharmaceuticals a patent for its invention, entitled: 'Methods and Compositions for Oral Administrations of Proteins'.
Oramed's POD (Protein Oral Delivery) technology is based research conducted at Jerusalem's Hadassah Medical Center. Oramed is seeking to advance the treatment of diabetes through its proprietary products. The company is currently developing an orally ingestible insulin capsule (ORMD-0801), which is currently in Phase II trials in patients with Type I and Type II diabetes under an IND application with the FDA; and an oral GLP-1 analogue capsule (ORMD-0901).